Airway Therapeutics, Inc.: Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

DSMC finds no safety concerns, allows use of highest dose for continued administration. Interim analysis of the trial expected in next month Company opens Spanish subsidiary to lead

Related Keywords

Spain ,Spanish ,Meghan Riley ,Marc Salzberg ,Airway Therapeutics ,European Medicines Agency ,Airway Spain ,Airway Therapeutics Inc ,Data Safety Monitoring Committee ,Chief Medical Officer Marc Salzberg ,Airway ,Herapeutics ,Ompletes ,Nose ,Escalation ,Hase ,Trial ,Elpultide ,Alfa ,Very ,Preterm ,Infants ,Risk ,Bronchopulmonary ,Dysplasia ,